WO2008107501A8 - Composition para el tratamiento de enfermedades infecciosas causadas por helicobacter - Google Patents

Composition para el tratamiento de enfermedades infecciosas causadas por helicobacter Download PDF

Info

Publication number
WO2008107501A8
WO2008107501A8 PCT/ES2008/000097 ES2008000097W WO2008107501A8 WO 2008107501 A8 WO2008107501 A8 WO 2008107501A8 ES 2008000097 W ES2008000097 W ES 2008000097W WO 2008107501 A8 WO2008107501 A8 WO 2008107501A8
Authority
WO
WIPO (PCT)
Prior art keywords
infectious diseases
diseases caused
helicobacter
composition
treating infectious
Prior art date
Application number
PCT/ES2008/000097
Other languages
English (en)
French (fr)
Other versions
WO2008107501A1 (es
Inventor
Javier Sancho Sanz
Adrián VELAZQUEZ CAMPOY
Nunilo Cremades Casasin
Original Assignee
Universidad De Zaragoza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Zaragoza filed Critical Universidad De Zaragoza
Priority to EP08750367A priority Critical patent/EP2130824A4/en
Priority to JP2009551230A priority patent/JP5478264B2/ja
Priority to US12/529,679 priority patent/US8367840B2/en
Publication of WO2008107501A1 publication Critical patent/WO2008107501A1/es
Publication of WO2008107501A8 publication Critical patent/WO2008107501A8/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuesto de fórmula general (I) para su uso en una composición farmacéutica para el tratamiento de enfermedades infecciosas causadas por Helicobacter pylori. R1 y R2 son O, S ó N, y pueden ser iguales o diferentes; R3 es O ó S; R4 es H ó un grupo alquilo (C1-C6); n toma valores de entre O a 3 y R5 es un radical NO2, COOR' ó SO3R', donde R' es un átomo de hidrógeno (H) ó un grupo alquilo (C1-C6).
PCT/ES2008/000097 2007-03-02 2008-02-22 Composition para el tratamiento de enfermedades infecciosas causadas por helicobacter WO2008107501A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08750367A EP2130824A4 (en) 2007-03-02 2008-02-22 COMPOSITION FOR THE TREATMENT OF HELICOBACTER-INFECTIOUS INFECTION DISEASES
JP2009551230A JP5478264B2 (ja) 2007-03-02 2008-02-22 ヘリコバクターにより引き起こされる感染症の治療のための組成物
US12/529,679 US8367840B2 (en) 2007-03-02 2008-02-22 Composition for treating infectious diseases caused by Helicobacter

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200700646 2007-03-02
ES200700646A ES2304221B1 (es) 2007-03-02 2007-03-02 Composicion para el tratamiento de enfermedades infecciosas causadas por helicobacter.

Publications (2)

Publication Number Publication Date
WO2008107501A1 WO2008107501A1 (es) 2008-09-12
WO2008107501A8 true WO2008107501A8 (es) 2009-10-08

Family

ID=39731847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2008/000097 WO2008107501A1 (es) 2007-03-02 2008-02-22 Composition para el tratamiento de enfermedades infecciosas causadas por helicobacter

Country Status (5)

Country Link
US (1) US8367840B2 (es)
EP (1) EP2130824A4 (es)
JP (1) JP5478264B2 (es)
ES (1) ES2304221B1 (es)
WO (1) WO2008107501A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128156A1 (en) * 2009-05-08 2010-11-11 Pike Pharma Gmbh 2,1,3-benzoxadiazol derivatives for the inhibition of influenza a and b virus and respiratory syncytial virus replication
WO2015104433A1 (es) * 2014-01-09 2015-07-16 Universidad De Zaragoza Derivados de benzo[c][1,2,5]oxadiazol para el tratamiento de enfermedades causadas por helicobater
ES2796148A1 (es) 2019-05-21 2020-11-25 Univ Zaragoza Compuestos para el tratamiento de enfermedades causadas por Helicobacter

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3394191A (en) * 1966-02-09 1968-07-23 Monsanto Co Phenyl beta-nitrostyryl sulfides
US3629465A (en) * 1966-08-22 1971-12-21 Givaudan Corp Preservatives for aqueous systems
US3985761A (en) * 1974-10-24 1976-10-12 Sarabhai Research Centre Nitrothiazolyl derivatives of nitrostyrene
WO1988003147A1 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US5763470A (en) 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
GB9526407D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Substances and their uses
CA2355714A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 7-aryl-6(z)heptatrienoic acid retinamides as apoptosis inducing compounds and their use as anti-cancer agents
DE10045599B4 (de) * 2000-09-15 2004-06-03 Wella Ag Haarfärbemittel auf der Basis von 4-Nitro-2,1,3-benzoxadiazol-Derivaten und dessen Verwendung als Farbstoff zum Färben von Haaren
US20040167189A1 (en) * 2002-03-22 2004-08-26 The Government Of The U.S.A., As Represented By The Secretary, Dept. Of Health And Human Services Materials and methods for inhibiting Wip1
ITRM20030194A1 (it) * 2003-04-24 2004-10-25 Univ Roma Uso di derivati del 7-nitro-2, 1, 3-benzossadiazolo per
WO2005082341A2 (en) 2004-02-23 2005-09-09 Prolexys Pharmaceuticals Inc. NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
WO2006002284A1 (en) * 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors

Also Published As

Publication number Publication date
JP5478264B2 (ja) 2014-04-23
EP2130824A1 (en) 2009-12-09
WO2008107501A1 (es) 2008-09-12
JP2010520182A (ja) 2010-06-10
ES2304221B1 (es) 2009-09-11
US20100063296A1 (en) 2010-03-11
US8367840B2 (en) 2013-02-05
EP2130824A4 (en) 2010-09-22
ES2304221A1 (es) 2008-09-16

Similar Documents

Publication Publication Date Title
WO2008107502A8 (es) Composicion para el tratamiento de enfermedades infecciosas
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
WO2008100867A3 (en) Novel inhibitors hepatitis c virus replication
WO2008021927A3 (en) Hepatitis c virus inhibitors
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
NO20084005L (no) Aminderivater
WO2008151460A3 (en) Cooling compounds
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
WO2008008776A3 (en) Hepatitis c virus inhibitors
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2007137066A3 (en) HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME
WO2008005511A8 (en) Novel inhibitors of hepatitis c virus replication
MX2009005048A (es) Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona.
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
WO2007118198A8 (en) 2-METHYLENE-1α,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF
ME00680B (me) Nova jedinjenja diozmetina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2007129066A8 (en) 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
HK1146710A1 (en) Radiopharmaceutical composition
UA105022C2 (uk) Композиція для боротьби з хворобами рослин та спосіб боротьби з хворобами рослин
WO2008107501A8 (es) Composition para el tratamiento de enfermedades infecciosas causadas por helicobacter

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08750367

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009551230

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008750367

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12529679

Country of ref document: US